Vedolizumab as a first-choice biological treatment of Crohn’s disease in a patient with paraganglioma of the nervous system

Patrycja Szałwińska; Ewa Malecka-Wojciesko

doi:10.5114/pg.2026.160317

eISSN: 1897-4317
ISSN: 1895-5770

Gastroenterology Review/Przegląd Gastroenterologiczny

Bieżący numer Archiwum Artykuły zaakceptowane O czasopiśmie Rada naukowa Bazy indeksacyjne Prenumerata Kontakt Zasady publikacji prac Opłaty publikacyjne

Panel Redakcyjny

Zgłaszanie i recenzowanie prac online

NOWOŚĆ

Portal dla gastroenterologów!

www.egastroenterologia.pl

Wyszukiwanie

Zasady redakcyjne

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

Otwarty dostęp

1/2026
vol. 21

Poleć ten artykuł:

Wyślij znajomemu

Skopiuj link:

Udostępnij:

List do Redakcji

Vedolizumab as a first-choice biological treatment of Crohn’s disease in a patient with paraganglioma of the nervous system

Patrycja Szałwińska

¹

,

Ewa Malecka-Wojciesko

²

Department of Digestive Tract Diseases, Medical University of Lodz, Poland
Department of Digestive Tract Diseases, Faculty of Medicine, Medical University of Lodz, Poland

Gastroenterology Rev 2026; 21 (1): 108–110

DOI: https://doi.org/10.5114/pg.2026.160317

Data publikacji online: 2026/03/06

Plik artykułu:

- Vedolizumab.pdf [0.07 MB]

Pobierz cytowanie

Metryki PlumX:

1. Conceição D, Saraiva MR, Rosa I, et al. Inflammatory bowel disease treatment in cancer patients – a comprehensive review. Cancers 2023; 15: 3130.

2. Jauregui-Amezaga A, Vermeire S, Prenen H. Use of biologics and chemotherapy in patients with inflammatory bowel diseases and cancer. Ann Gastroenterol 2016; 29: 127-36.

3. Beaugerie L, Carrat F, Colombel JF, et al. Risk of new or recurrent cancer under immunosuppressive therapy in patients with IBD and previous cancer. Gut 2014; 63: 1416-23.

4. Poullenot F, Laharie D. Management of inflammatory bowel disease in patients with current or past malignancy. Cancers 2023; 15: 1083.

5. Colombel J, Sands BE, Rutgeerts P, et al The safety of vedolizumab for ulcerative colitis and Crohn’s disease. Gut 2017; 66: 839-51.

6. Vedamurthy A, Gangasani N, Ananthakrishnan AN. Vedolizumab or tumor necrosis factor antagonist use and risk of new or recurrent cancer in patients with inflammatory bowel disease with prior malignancy: a retrospective cohort study. Clin Gastroenterol Hepatol 2022; 20: 88-95.

7. Gordon H, Biancone L, Fiorino G, et al. ECCO guidelines on inflammatory bowel disease and malignancies. J Crohns Colitis 2023; 17: 827-54.

Copyright: © 2026 Termedia Sp. z o. o. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.

Vedolizumab as a first-choice biological treatment of Crohn’s disease in a patient with paraganglioma of the nervous system

Patrycja Szałwińska 1 , Ewa Malecka-Wojciesko 2

Patrycja Szałwińska

¹

,

Ewa Malecka-Wojciesko

²